Ophthalmic adverse effects of taxanes: The Mayo Clinic experience
- PMID: 33148049
- DOI: 10.1177/1120672120969045
Ophthalmic adverse effects of taxanes: The Mayo Clinic experience
Abstract
Purpose: To investigate ophthalmic side effects of taxanes and compare side effect frequency, requirement for cessation of taxane therapy, visual acuity outcome, and concurrent systemic effects between paclitaxel and docetaxel.
Methods: Patients taking taxanes at a single center from 1/1/2010 to 2/29/2020 were retrospectively reviewed for clinical characteristics, treatments, and concurrent systemic adverse effects.
Results: Of 1918 patients, 22 (1.1%) experienced an ophthalmic side effect that came to the attention of an eye care provider. Mean age at presentation of the side effect was 62 years (median 66, range 23-82). The most common side effect was meibomian gland dysfunction in 5 (23%) patients, followed by cystoid macular edema in 4 (18%) patients and canalicular obstruction in 4 (18%) patients, followed by diplopia in 2 (9%) patients, and singular cases of lash alopecia, and blepharitis, among others. Lids/lashes as well as nasolacrimal duct adverse effects occurred more frequently with docetaxel therapy than with paclitaxel therapy. Follow-up was available in 10 (45%) patients, with mean duration of 5 months (median 4, range 0-12 months). Of these patients, the ophthalmic side effects were resolved or controlled without discontinuing therapy in 8 (80%) patients. Taxane cessation was required in one patient with docetaxel-related canalicular obstruction and one patient with paclitaxel-related cystoid macular edema.
Conclusion: Ophthalmic taxane-related adverse events are rare with estimated frequency of ophthalmic side effects of about 1%. Nevertheless, it is important that ophthalmologists recognize the range of side effects for optimal management. Most ophthalmic events can be treated with targeted therapy without discontinuation of life-prolonging taxane therapy.
Keywords: Taxanes; cabazitaxel; canalicular obstruction; cystoid macular edema; docetaxel; ophthalmic adverse effects; paclitaxel; protein-bound paclitaxel; punctal stenosis.
Similar articles
-
POSSIBLE EFFICACY OF TOPICAL DORZOLAMIDE IN THE TREATMENT OF PACLITAXEL-RELATED CYSTOID MACULAR EDEMA.Retin Cases Brief Rep. 2018 Winter;12(1):75-79. doi: 10.1097/ICB.0000000000000433. Retin Cases Brief Rep. 2018. PMID: 27749791
-
Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.JAMA Ophthalmol. 2022 Sep 1;140(9):880-884. doi: 10.1001/jamaophthalmol.2022.3026. JAMA Ophthalmol. 2022. PMID: 35951320 Free PMC article.
-
Regression of taxane-related cystoid macular edema after topical dorzolamide treatment: two case reports.J Med Case Rep. 2021 Jul 21;15(1):355. doi: 10.1186/s13256-021-02954-8. J Med Case Rep. 2021. PMID: 34284818 Free PMC article.
-
A cross-sectional optical coherence tomography study in patients on taxane-based therapy and a case report with the literature review.Cutan Ocul Toxicol. 2020 Sep;39(3):287-293. doi: 10.1080/15569527.2020.1790592. Epub 2020 Jul 9. Cutan Ocul Toxicol. 2020. PMID: 32619362 Review.
-
Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?J Oncol Pharm Pract. 2012 Jun;18(2):250-6. doi: 10.1177/1078155211409473. Epub 2011 Aug 1. J Oncol Pharm Pract. 2012. PMID: 21807762 Review.
Cited by
-
Taxane-associated retinopathy and radiation-induced optic neuropathy in a young female patient with metastatic breast cancer.GMS Ophthalmol Cases. 2025 Jul 15;15:Doc07. doi: 10.3205/oc000255. eCollection 2025. GMS Ophthalmol Cases. 2025. PMID: 40859984 Free PMC article.
-
Cystoid macular oedema without leakage in fluorescein angiography: a literature review.Eye (Lond). 2023 Jun;37(8):1519-1526. doi: 10.1038/s41433-022-02230-z. Epub 2022 Sep 10. Eye (Lond). 2023. PMID: 36088420 Free PMC article. Review.
-
Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention.Curr Oncol. 2024 Sep 23;31(9):5709-5721. doi: 10.3390/curroncol31090423. Curr Oncol. 2024. PMID: 39330051 Free PMC article. Review.
-
Identification and validation of a small molecule targeting ROR1 for the treatment of triple negative breast cancer.Front Cell Dev Biol. 2023 Sep 13;11:1243763. doi: 10.3389/fcell.2023.1243763. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37779899 Free PMC article.
-
A review on drug-induced dry eye disease.Indian J Ophthalmol. 2023 Apr;71(4):1263-1269. doi: 10.4103/IJO.IJO_2782_22. Indian J Ophthalmol. 2023. PMID: 37026257 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources